Cord blood banking market to reach $49.85B

The first successful cord blood transplant was performed in 1988 at the Saint-Louis Hospital in Paris. It treated a five-year-old boy with Fanconi's Anemia, a rare genetic disease, using stem cells from his newborn sister's umbilical cord. Stem cells from cord blood are currently used to treat more than 80 diseases. These include various forms of leukemia and lymphoma, as well as blood disorders like sickle-cell anemia and inherited metabolic or immune system disorders. Parents have two main options: public or private banking. Public banks accept donations for anyone in need at no cost to the donor, while private banks charge fees to store cord blood for a family's exclusive use. Private banking can involve an initial fee of over $2,000 and annual storage costs of several hundred dollars. The American Academy of Pediatrics has described the practice of private banking for a child without a known high-risk medical condition as "unwarranted biological insurance." The probability of a child using their own banked cord blood is estimated to be as low as 1 in 200,000. For certain cancers like leukemia, a child's own stem cells may not be used due to the risk they already contain the malignant cells. Cord blood transplants do not require as strict of a genetic match as bone marrow, making them a vital option for patients from ethnically diverse backgrounds who often struggle to find a suitable donor. Researchers are also studying cord blood's potential in regenerative medicine for conditions like cerebral palsy, spinal cord injury, and heart disease.